BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/16/2024 6:17:49 AM | Browse: 350 | Download: 858
Publication Name World Journal of Clinical Oncology
Manuscript ID 91968
Country Spain
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Neoadjuvant treatment of rectal cancer: Where we are and where we are going
Manuscript Source Invited Manuscript
All Author List Elísabet González Del Portillo, Felipe Couñago and Fernando López-Campos
ORCID
Author(s) ORCID Number
Elísabet González Del Portillo http://orcid.org/0000-0002-0758-8156
Felipe Couñago http://orcid.org/0000-0001-7233-0234
Fernando López-Campos http://orcid.org/0000-0002-4077-0507
Funding Agency and Grant Number
Corresponding Author Felipe Couñago, MD, PhD, Doctor, Doctor, Department of Radiation Oncology, GenesisCare Madrid, Modesto La Fuente, Madrid 28010, Spain. fcounago@gmail.com
Key Words Locally advanced rectal cancer; Total neoadyuvant treatment; Radiotherapy; Biomarker; Magnetic resonance imaging; Conservative organ strategy; Watch and wait
Core Tip The treatment of rectal cancer is well-established, based on total neoadjuvant treatment followed by deferred surgery. However, the development of biomarkers is necessary to predict which patients will achieve a complete pathological response and, therefore, may not require surgical treatment. The advent of new imaging techniques and their morphological, metabolic, and functional information pave the way for defining criteria for patients with locally advanced rectal cancer who are candidates for a conservative strategy.
Publish Date 2024-07-16 06:17
Citation

González Del Portillo E, Couñago F, López-Campos F. Neoadjuvant treatment of rectal cancer: Where we are and where we are going. World J Clin Oncol 2024; 15(7): 790-795

URL https://www.wjgnet.com/2218-4333/full/v15/i7/790.htm
DOI https://dx.doi.org/10.5306/wjco.v15.i7.790
Full Article (PDF) WJCO-15-790-with-cover.pdf